| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised … MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ... The Lancet 395 (10231), 1208-1216, 2020 | 1578 | 2020 |
| Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and … M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ... European urology 70 (6), 926-937, 2016 | 1134 | 2016 |
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 1039 | 2018 |
| Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution … M Perera, N Papa, M Roberts, M Williams, C Udovicich, I Vela, ... European urology 77 (4), 403-417, 2020 | 866 | 2020 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 781* | 2021 |
| Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation MS Hofman, WFE Lau, RJ Hicks Radiographics 35 (2), 500-516, 2015 | 534 | 2015 |
| 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging … J Calais, F Ceci, M Eiber, TA Hope, MS Hofman, C Rischpler, ... The Lancet Oncology 20 (9), 1286-1294, 2019 | 414 | 2019 |
| Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ... Journal of Nuclear Medicine 60 (4), 517-523, 2019 | 404 | 2019 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 383 | 2020 |
| Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls MS Hofman, RJ Hicks, T Maurer, M Eiber Radiographics 38 (1), 200-217, 2018 | 355 | 2018 |
| International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ... Journal of Nuclear Medicine 54 (5), 683-690, 2013 | 347 | 2013 |
| Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial S Siva, M Bressel, DG Murphy, M Shaw, S Chander, J Violet, KH Tai, ... European urology 74 (4), 455-462, 2018 | 311 | 2018 |
| The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ... Haematologica 99 (6), 1107, 2014 | 295 | 2014 |
| The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the … L Emmett, J Buteau, N Papa, D Moon, J Thompson, MJ Roberts, K Rasiah, ... European urology 80 (6), 682-689, 2021 | 292 | 2021 |
| E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET F Ceci, DE Oprea-Lager, L Emmett, JA Adam, J Bomanji, J Czernin, ... European journal of nuclear medicine and molecular imaging 48, 1626-1638, 2021 | 286 | 2021 |
| High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours MS Hofman, G Kong, OC Neels, P Eu, E Hong, RJ Hicks Journal of medical imaging and radiation oncology 56 (1), 40-47, 2012 | 278 | 2012 |
| Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration … J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ... Journal of Nuclear Medicine 61 (6), 857-865, 2020 | 268 | 2020 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 249 | 2019 |
| Prostate-specific membrane antigen ligands for imaging and therapy M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ... Journal of Nuclear Medicine 58 (Supplement 2), 67S-76S, 2017 | 229 | 2017 |
| Is there still a role for SPECT–CT in oncology in the PET–CT era? RJ Hicks, MS Hofman Nature reviews Clinical oncology 9 (12), 712-720, 2012 | 189 | 2012 |
Professor Rod HicksDepartment of Medicine, St Vincent's Hospital, the University of Melbourne and Department ofBestätigte E-Mail-Adresse bei mtic.net.au